In October 2026, Boston will host the 13th Aging Research & Drug Discovery Meeting—a gathering that marks aging science's passage from academic fringe to pharmaceutical mainstream. Where longevity research once lived in isolated university labs, it now draws ten major pharmaceutical companies, venture capital, and entrepreneurs united by a shared conviction: that the biology of aging can be translated into medicines that extend not just lifespan, but the years lived well. This convergence at Harvard reflects a deeper shift in how civilization is beginning to reckon with time itself—not as an i